India's first shipment under COVAX likely this week: WHO chief scientist

She said this in reply to the question of whether WHO would start rolling out the COVAX facility officially to other countries in the next couple of months

Soumya Swaminathan
Soumya Swaminathan. Photo courtesy: @doctorsoumya
Press Trust of India Hyderabad
2 min read Last Updated : Feb 22 2021 | 11:07 PM IST

The first shipment from India

under COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for all countries, is likely to roll out this week, WHO Chief Scientist Soumya Swaminathan said on Monday.

"Not in the next couple of months. This week. (I think) today or tomorrow, the first shipment from India, from the Serum Institute, will be going out to at least 25 or 30 countries and then we hope that this will be followed by the vaccines also that are being manufactured in India.

Many countries around the world are waiting for the distribution to happen as they have been watching vaccination programmes beginning and scaling in high income countries, while their own healthcare workers and other vulnerable groups are still waiting," she said, during a virtual panel discussion.

She said this in reply to question whether WHO would start rolling out the COVAX facility officially to other countries in the next couple of months.

The panel discussion on 'Immunizing the World' was held during 'BioAsia-2021', the flagship annual life sciences event of the Telangana government.

The role being played by India needs to be recognised and the country has risen to the occasion, expanding its huge manufacturing capacity, she said.

Observing that "amazing" Research and Development is also happening in India with a lot of innovative products in clinical trials, she hoped that they would also be successful.

Asked what it takes for countries to overcome the pandemic, she said it would be solidarity, global collaboration and unity.

"Because, it's clear that a pandemic cannot be addressed on a country-by-country or a region-by-region basis," she said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :WHOCoronavirus Vaccine

First Published: Feb 22 2021 | 11:01 PM IST

Next Story